Denali Therapeutics's total assets for Q2 2026 were $1.16B, a decrease of -8.54% from the previous quarter. DE:4DN total liabilities were $322.78M for the fiscal quarter, a -5.04% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.